Defence Therapeutics Inc.
DTC
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 32.65% | 90.60% | 72.84% | 23.44% | 0.83% |
| Total Depreciation and Amortization | -43.84% | -- | 36.84% | 5,816.67% | 10,850.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 114.09% | -96.90% | 82.80% | 10,000.00% | -1,462.02% |
| Change in Net Operating Assets | -202.45% | -- | -26.49% | 244.87% | 303.43% |
| Cash from Operations | 19.69% | -- | 106.05% | 75.69% | -29.45% |
| Capital Expenditure | -- | -- | -- | 435.14% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -- | -- | 435.14% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 39.19% | -- | -89.12% | -225.81% | -496.77% |
| Issuance of Common Stock | 124.88% | -- | -- | -99.31% | -60.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -98.56% | -- | -- | 100.00% | 43.13% |
| Cash from Financing | 116.39% | -- | 13.76% | -97.29% | -62.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 319.12% | -- | 105.09% | -430.43% | -130.87% |